Lance1564 wrote:I've yet to find out if my neurologist agrees with any of the theories behind a permeability issue with the BBB or CCSVI. I have a strong feeling he doesn't. So I've kept that part of my treatment in the hands of the IRs.
http://msj.sagepub.com/content/9/6/540.shortDysregulation of the BBB and transendo thelial migration of activated leukocytes are among the earliest cerebrovascular abnormalities seen in multiple sclerosis (MS) brains and parallel the release of inflammatory cytokines/chemokines. Mechanisms for breakdown of the BBB in MS are incompletely understood, but appear to involve direct effects of these cytokines/chemokines on endothelial regulation of BBB components, as well as indirect cytokine/chemokine-dependent leukocyte mediated injury.
Regarding my procedure: In all honesty, my results were profound.
It is about three to four doctors in the IR department that are treating the condition under the Chief. It's a well-known medical center in the south where this is being done.
This was a tough decision for me to go back so soon. I understand the potential for the vein to go right back to baseline even after a 2nd procedure, particularly considering the fact that I restenosed so quickly.
As I mentioned, I had an 80% stenosis of the right jugular vein just under the clavicle.
Yeah, I think so too. The capillary endothelial cell junctions in the BBB are ten times tighter than what normal capillary junctions are elsewhere in the body. It's made that way for a reason! If it was ok for everything to pass freely into our brains, we wouldn't have those extra tight junctions.I get the feeling that any agent (virus, bacteria, iron, organic solvent, etc.) would damage neurons if they're able to cross the BBB.
Section 8, Exposure controls/personal protection lists OSHA's Permissible Exposure Limits (PELs); Threshold Limit Values (TLVs); appropriate engineering controls; personal protective equipment (PPE).
Section 11, Toxicological information includes routes of exposure; related symptoms, acute and chronic effects; numerical measures of toxicity.
Employers must ensure that SDSs are readily accessible to employees.
Users browsing this forum: ALA